碱性磷酸酶（ALP）在一定程度上反映了多发性骨髓瘤（MM）患者病情的变化。然而，ALP 与 MM 的关系仍不确定。我们的研究旨在确定初诊MM患者的初始ALP水平与总生存率之间的关系。收集了2012年至2016年北京朝阳医院202例初诊MM患者的临床数据。记录基线特征、疾病进展分期、血清标志物和患者生存数据。 ALP 的临界值是根据患者生存数据计算的，并将患者分组。比较不同组患者3年、5年生存率、肝功能、骨病等指标的差异。使用 COX 回归分析确定影响新诊断 MM 患者的独立危险因素。根据 ALP 截止点将患者分为三组：第 1 组（ALP <70 U/L）、第 2 组（ALP 70 至 <120 U/L） L) 和第 3 组 (ALP ≥120 U/L)。不同ALP组间乳酸脱氢酶、血钙、白细胞计数、血红蛋白及肝功能指标（包括丙氨酸转氨酶、天冬氨酸转氨酶、白蛋白、γ-谷氨酰转移酶）差异有统计学意义（P<0.05）。不同骨病分级患者ALP水平差异显着（P<0.05）。第 1、2 和 3 组的中位生存时间分别为 25、52 和 31 个月。与其他两组相比，第2组的3年生存率显着较高（P=0.006），而三组的5年生存率没有显着差异（P=0.51）。年龄、国际分期系统分期、天冬氨酸转氨酶、β2-微球蛋白、ALP分级和严重骨病被确定为影响初诊患者生存的独立因素（P<0.05）。ALP水平与MM患者的预后相关， ALP 范围为 70 至 <120 U/L 反映了更好的生存预期。2024 转化癌症研究。版权所有。

Alkaline phosphatase (ALP) reflects changes in the condition of multiple myeloma (MM) patients to some extent. However, the relationship of ALP in MM remains uncertain. Our study aimed to determine the association between initial ALP levels and overall survival in newly diagnosed MM patients.Clinical data from 202 newly diagnosed MM patients at Beijing Chaoyang Hospital between 2012 and 2016 were collected. Baseline characteristics, disease progression staging, serum markers, and patient survival data were recorded. The cut-off value for ALP was calculated based on patient survival data, and patients were divided into groups. Differences in patients' 3- and 5-year survival rates, liver function, bone disease and other indicators among different groups were compared. Independent risk factors influencing newly diagnosed MM patients were identified using COX regression analysis.Patients were categorized into three groups based on ALP cut-off points: Group 1 (ALP <70 U/L), Group 2 (ALP 70 to <120 U/L), and Group 3 (ALP ≥120 U/L). Significant differences were observed in lactate dehydrogenase, serum calcium, white blood cell count, hemoglobin, and liver function indicators (including alanine aminotransferase, aspartate aminotransferase, albumin, and γ-glutamyl transferase) among different ALP groups (P<0.05). ALP levels varied significantly among patients with different bone disease grades (P<0.05). Median survival times for Groups 1, 2, and 3 were 25, 52, and 31 months, respectively. Group 2 exhibited significantly higher 3-year survival compared to the other two groups (P=0.006), while no significant difference was observed in 5-year survival among the three groups (P=0.51). Age, International Staging System staging, aspartate aminotransferase, β2-microglobulin, ALP grading, and severe bone disease were identified as independent factors influencing survival in newly diagnosed patients (P<0.05).ALP levels are correlated with the prognosis of MM patients, and an ALP range of 70 to <120 U/L reflects a better survival expectation.2024 Translational Cancer Research. All rights reserved.